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Timing of autologous stem cell transplantation from last
chemotherapy affects lymphocyte collection and survival in
non-Hodgkin lymphoma
The infused autograft absolute lymphocyte count (A-ALC) is
an independent prognostic factor for survival in non-
Hodgkin lymphoma (NHL) status after autologous stem
cell transplantation (ASCT) (Porrata et al, 2004). An A-ALC
is dependent on the preaphaeresis absolute lymphocyte
count (PA-ALC) at the time of aphaeresis (Porrata et al,
2004). The factors affecting PA-ALC, as a surrogate marker
of the host immune status at the time of aphaeresis, remain
unknown. This study evaluated the hypothesis that PA-ALC
is directly dependent upon the time interval from last
chemotherapy (TILC), as a marker of immune recovery time
from the myelosuppressive effects of chemotherapy prior to
proceeding with aphaeresis collection.
Patients and methods
Patient population
From 1996 to 2001, 160 consecutive NHL patients underwent
autologous peripheral blood stem cell transplantation at our
institution. All patients were included in this retrospective
study, in which the data were prospectively collected over time
and entered into a computerised database. Response to
therapy, relapse and survival, data were updated continuously.
No patients were lost to follow-up. All patients gave written,
informed consent allowing the use of their medical records for
medical research. Approval of the study was obtained from the
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Summary
Autograft absolute lymphocyte count (A-ALC) is a prognostic factor for
survival in non-Hodgkin lymphoma (NHL) after autologous stem cell
transplantation (ASCT). An A-ALC is dependent upon the preaphaeresis
absolute lymphocyte count (PA-ALC) at the time of aphaeresis. It was
hypothesised that the time interval from last chemotherapy (TILC) to
aphaeresis affects PA-ALC. One hundred and sixty consecutive NHL patients
who underwent ASCT at the Mayo Clinic between 1996 and 2001 were
evaluated. A strong correlation between TILC and PA-ALC (r ¼ 0Æ67,
P <0 Æ0001) was identiﬁed. Higher PA-ALC was observed in TILC ‡55 d
compared with TILC <55 d [median: 7Æ0 vs. 3Æ8 · 10
9/l], P <0 Æ0001). TILC
as a continuous variable was identiﬁed as a prognostic factor for overall
survival (OS) [hazard ratio (HR) ¼ 0Æ989, P <0 Æ01] and progression-free
survival (PFS) (HR ¼ 0Æ992, P <0 Æ0492). Median OS and PFS were longer in
the TILC ‡55 d vs. TILC <55 d group (not reached vs. 21 months,
P <0 Æ0008; 76 vs. 9 months, P <0 Æ0025, respectively). Multivariate
analysis demonstrated TILC to be an independent prognostic indicator for
OS and PFS. These ﬁndings suggest that the immune status of the host at the
time of aphaeresis may predict survival after ASCT.
Keywords: chemotherapy, absolute lymphocyte count, non-Hodgkin lym-
phoma, autologous stem cell transplantation, survival.
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Objectives of the study
The primary objective of the study was to assess the correlation
between TILC and PA-ALC. The secondary objective was to
determine the impact on overall survival (OS) and progres-
sion-free survival (PFS) based on TILC. The REMARK
(REporting recommendations for tumour MARKer prognostic
studies) guidelines (McShane et al, 2005) were used to report
TILC as a prognostic factor for survival. The PA-ALC was
calculated from the complete blood cell count (CBC) per-
formed prior to each aphaeresis collection. The absolute white
blood cell count (WBC) from the autograft was calculated as
follows: autograft bag volume (ml) · autograft WBC cells/ml
(·10
9 cells/l) · 0Æ001. The autograft WBC was obtained using
the ACT 10 Series Analyzer Coulter, Miami, FL, USA and the
percentage of lymphocytes was determined microscopically
using Wright stain. The A-ALC for each collection was
calculated as follows: [(total absolute WBC) · (% Lympho-
cytes)]/kg. Absolute lymphocyte count at day 15 (ALC-15)
after ASCT was obtained from the CBC at day 15 post-ASCT.
Prognostic factors
The international age-adjusted prognostic index [age (‡60 vs.
<60 years), lactate dehydrogenase (LDH) >normal for age/sex,
performance status (PS) (‡2 vs. <2), extranodal sites (‡2 vs.
<2) and stage (I/II vs. III/IV)] at the time of transplantation, in
addition to clinical response status before transplantation,
were used in the study.
Peripheral blood stem cell collection
Patientsreceived granulocyte-colony stimulating-factor (10 lg/
kg/d) for ﬁve to seven consecutive days by subcutaneous
injection.Patientsunderwentdailyaphaeresiscollectionsuntila
target of 2Æ0 · 10
6CD34 cells/kg or greater was achieved. There
were no purged or CD34-selected stem cells collections.
Conditioning regimens
In total, 90 patients received BEAM [BCNU (carmustine;
300 mg/m
2), etoposide (100 mg/m
2), cytarabine (ARA-C)
(100 mg/m
2) and melphalan (140 mg/m
2)], 62 patients
received BEAC [BCNU (140 mg/m
2), etoposide (100 mg/
m
2), ARA-C (100 mg/m
2) and cyclophosphamide (35 mg/
kg)] and eight patients received cyclophosphamide (60 mg/
m
2) and total body irradiation (TBI) (12 Gy).
Response and survival
Response criteria were based on the guidelines from the NHL
International Workshop (Cheson et al, 1999). Complete
response (CR) was deﬁned as complete regression of all
measurable or evaluable disease including radiologically dem-
onstrable disease, bone marrow involvement or peripheral
blood involvement. Partial (PR) was deﬁned as a reduction in
the sum of the products of measurable lesions’ longest
diameter and perpendicular diameters of 75% or greater, with
a 50% or greater decrease in hepatomegaly or splenomegaly
(measured from the costal margin), if there was previous
known liver or spleen involvement. Stable disease was deﬁned
as less than PR, but was not progressive disease. Disease
progression was deﬁned as a 50% or more increase in the sum
of the products of the longest diameter and the perpendicular
diameter of measurable lesion (S) from the prestudy meas-
urement, the appearance of new lesions, or a 2-cm increase in
spleen or liver size because of lymphoma. Relapsed disease was
deﬁned as the appearance of any new lesion or increase by 50%
or more in the size of previously involved sites.
Overall survival was measured from the date of transplan-
tation to the date of death or last follow-up. PFS was deﬁned as
the time from transplantation to disease progression, relapse,
death or last follow-up. Those who died were considered to
have had disease progression unless documented evidence
clearly indicated that no progression had occurred.
Statistical analysis
Overall survival and PFS were analysed using the approach
of Kaplan and Meier (1958). Differences between survival
curves were tested for statistical signiﬁcance using the two-
tailed log-rank test. TILC was assessed as a continuous
variable and dichotomised based on ﬁnding the optimal cut-
off point based on the log-rank statistic (Crowley & McCoy,
1993). Cox proportional hazards model (Cox, 1972) was
used to evaluate TILC as a prognostic factor for post-
transplant OS and PFS times as well as to assess and adjust
for other known prognostic factors. Risk ratios reported are
for risks associated with patients having a TILC ‡55 d vs.
TILC <55 d. Other prognostic factors tested included age
(‡60 vs. <60 years), LDH >normal for age/sex, PS (‡2 vs.
<2), extranodal sites (‡2 vs. <2), stage (I/II vs. III/IV), CR
status at transplantation and international prognostic index
(IPI) ‡2.
In addition to the evaluation of TILC and its prognostic
signiﬁcance for OS and PFS, its utility as a marker for PA-ALC
(‡5 · 10
9/l) was also assessed. This cut-off and deﬁnition of
PA-ALC was based on our previous publication. The choice of
optimal cut-off of TILC was based on its utility as a marker of
PA-ALC using box plot, receiver-operator characteristic
(ROC) curves, and area under the curve (AUC) analyses as
well as its prognostic value for post-transplant OS. Chi squared
tests were used to determine relationships between categorical
variables; the Wilcoxon’s rank-sum tests were used to deter-
mine associations between categorical and continuous varia-
bles, and Spearman’s correlation coefﬁcients were used to
evaluate associations for continuous variables. All P-values
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declared at P <0 Æ05.
Results
Patient characteristics
The median age at the time of transplantation for the study
cohort was 54 years (range: 23–73). Distributions of additional
baseline characteristics for these patients are presented in
Table I and are summarised according to TILC <55 d vs.
‡55 d. No differences between the groups were identiﬁed for
patient characteristics or prognostic factors. CHOP (cyclopho-
sphamide, hydroxydaunomycin, oncovin and prednisone)
followed by DHAP (dexamethasone, high-dose ARA-C and
platinol) was the most frequent (31% of the cases) chemother-
apy combination used prior to ASCT. Other regimens used
included ESHAP (etoposide, Solu-Medrol, ARA-C and plati-
nol), ﬂudarabine, ICE (ifosfamide, carboplatin and etoposide),
MINE (mesna, ifosfamide, novantrone and etoposide), pro-
mace-cytobom (prednisone, methotrexate, adriamycin, cyclo-
phosphamide, etoposide, cytarabine, bleomycin, oncovin and
methotrexate) and VANDERBILT. We identiﬁed no associa-
tion between the chemotherapy regimens and TILC as a
continuous variable (P ¼ 0Æ25) or TILC ‡55 d as a dicho-
tomised variable (P ¼ 0Æ31).
The median follow-up was 34Æ5 months (range: 1–
145 months). At the time of these analyses, 84 patients
(53%) had died. Seventy-six patients died of lymphoma. In
the TILC <55 d group, two patients died of acute respiratory
distress syndrome, one patient of pneumonia, one patient of
acute myeloid leukemia and one patient of chronic myeloid
leukemia. In the TILC ‡55 d group, two patients died of acute
myeloid leukemia and one patients of renal failure. None of the
patients developed clinically evident autologous graft-versus-
host-disease.
Role of TILC on PA-ALC
In an attempt to identify factors that inﬂuence PA-ALC, we
assessed the utility of TILC, as a marker of immune recovery
time from the myelosuppressive effects of chemotherapy prior
to proceeding with aphaeresis collection. Box plot analysis
showed that the median TILC was signiﬁcantly higher in those
patients with a PA-ALC ‡5 · 10
9/l vs. PA-ALC <5 · 10
9/l at
the time of aphaeresis collection (70 d vs. 43 d respectively
P <0 Æ0001). An ROC and sensitivity/speciﬁcity curves and
AUC analyses showed that TILC was a signiﬁcant marker for
PA-ALC (AUC ¼ 0Æ86, P <0 Æ0001). Based on these results, as
well as evaluating various TILC cut-off points as prognostic
factors for OS, TILC ‡55 d was considered optimal. Therefore,
this cut-off point was evaluated for TILC in all subsequent
analyses in this study.
With regard to the association between TILC and PA-ALC,
these dichotomised variables were found to be signiﬁcantly
correlated with each other (P <0 Æ0001) as were their
continuous counterparts (rs ¼ 0Æ67, P <0 Æ0001) (Fig 1). No
other patient characteristic or prognostic factor was found to
be associated with PA-ALC. A strong association was found
Table I. Baseline characteristics of patients according to the time
interval from last chemotherapy (TILC) to peripheral blood absolute
lymphocyte count at the time of stem cell mobilisation and collection.
Characteristics
TILC <55 d
(n ¼ 89)
TILC ‡55 d
(n ¼ 71) P-value
Age(years)
Median, range 52 (23–73) 54 (31–72) 0Æ96
Gender
Female 31 27 0Æ74
Male 58 44
Histology
Diffuse large cell 59 45 0Æ10
Mantle cell 6 9
Follicular 12 15
T cell 9 1
Other 3 1
Prognostic factors at time of autologous stem cell transplantation
(ASCT)
Age
‡60 years 29 21 0Æ73
LDH
>Normal 30 20 0Æ49
Performance status
<2 84 68 0Æ68
Extranodal sites
<2 84 69 0Æ46
Stage
III/IV 63 45 0Æ40
International prognostic index
01 9 1 6 0 Æ62
13 5 3 0
22 3 2 0
31 2 5
Number of pretransplant regimens
11 4 1 0 0 Æ45
25 3 4 4
31 9 1 1
43 6
Clinical outcome pre-ASCT
Complete remission 10 12 0Æ50
Partial remission 74 56
First relapse 1 1
Second relapse 2 0
Refractory 2 2
Conditioning regimens
BEAC 33 29 0Æ45
BEAM 53 37
CTX/TBI 3 5
BEAC ¼ BCNU, etoposide, cytarabine, and cyclophosphamide;
BEAM ¼ BCNU, etoposide, cytarabine, and melphalan; CTX/TBI,
cyclophosphamide/total body irradiation; LDH, lactate dehydrogenase.
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between A-ALC and ALC-15 (rs ¼ 0Æ67, P <0 Æ0001), as
reported before (Porrata et al, 2004). Because of the strong
associations between PA-ALC with A-ALC and A-ALC with
ALC-15, when these values were compared between the TILC
groups, higher values were found in the TILC ‡55 d compared
with TILC <55 d (Table II).
Post-transplant survival and TILC
The median post-transplant OS (Fig 2) and PFS (Fig 3) times
were signiﬁcantly better for patients with a TILC ‡55 d
compared with patients with a TILC <55 d (not reached vs.
21 months, P <0 Æ0008; not reached vs. 9 months, P <0 Æ0025,
respectively). Signiﬁcant factors in the univariate analysis for
OS included TILC (as a continuous and dichotomised
variable), LDH, PS and IPI (Table III). In the multivariate
analysis (Table IV), TILC remained a signiﬁcant factor when
compared with LDH, PS and IPI. Similarly, univariate analysis
showed that TILC (as a continuous and dichotomised variable)
was a signiﬁcant factor for PFS, in addition to the IPI
(Table III). Multivariate analyses showed the TILC remained a
signiﬁcant factor when compared with the IPI (Table IV).
Given the strong correlation and agreement between TILC and
PA-ALC/A-ALC/ALC-15, only TILC was included in the
multivariate model.
Discussion
The best timing to undergo ASCT has been reported when
patients have minimal residual disease or ﬁrst CR and in
patients who have not received multiple prior chemotherapy
treatments (Phillip et al, 1995; Kiss et al, 2005). To our
knowledge, no study has looked at the best timing to proceed
with ASCT based on the immune status of the host. We
have reported that A-ALC is a prognostic factor for survival
post-ASCT in NHL (Porrata et al, 2004). An A-ALC is
dependent on PA-ALC, as a surrogate marker of immune
status of the host at the time of aphaeresis (Porrata et al, 2004).
It was hypothesised that TILC, as a marker of immune
recovery after the myelosuppressive effect of chemotherapy,
affects PA-ALC. Therefore, we set out to identify if TILC
inﬂuences PA-ALC and clinical outcomes of NHL patients
treated with ASCT.
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Fig 1. Scatterplot comparing time interval from last chemotherapy
(TILC) (days) and preaphaeresis absolute lymphocyte count (PA-ALC)
(·10
9/l). A strong positive correlation was identiﬁed between TILC and
PA-ALC. (Spearman’s correlation rho factor, r ¼ 0Æ67, P <0 Æ0001).
Table II. Comparison of PA-ALC/A-ALC/ALC-15 between TILC
groups.
Factors TILC <55 d TILC ‡55 d P-values
PA-ALC, median (range) 3Æ8( 0 Æ56–9Æ53) 7Æ0( 1 Æ55–22Æ1) <0Æ0001
A-ALC, median (range) 0Æ38 (0Æ41–1Æ44) 0Æ65 (0Æ04–2Æ21) <0Æ0001
ALC-15, median (range) 0Æ35 (0Æ07–1Æ06) 0Æ56 (0Æ04–6Æ99) <0Æ0001
ALC-15, absolute lymphocyte count at day 15 postautologous stem cell
transplantation (·10
9/l); A-ALC, autograft absolute lymphocyte count
(·10
6/kg); PA-ALC, preaphaeresis absolute lymphocyte count (·10
9/l).
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Fig 2. Overall survival of patients with TILC ‡55 d vs. patients with a
TILC <55 d. The median OS was not reached in the TILC ‡55 d group
and was 21 months in the TILC <55 d group. The OS rates at 5 years
were 64% and 39%, respectively (P <0 Æ0008).
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Fig 3. Progression-free survival (PFS) of patients with TILC ‡55 d vs.
patients with a TILC <55 d. The median PFS was 76 months in the
TILC ‡55 d group and 9 months in the TILC <55 d group. The OS
rates at ﬁve years were 52% and 31%, respectively (P <0 Æ0025).
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was balanced for all patients’ characteristics and prognostic
factors. The time to proceed to ASCT from last chemotherapy
was based on the availability of the aphaeresis and bone
marrow transplantation unit to accommodate the patient. The
reason for the different conditioning regimens is based on our
evolving clinical practice, as cyclophosphamide/TBI was ori-
ginally used at the start of our transplant programme, followed
by BEAC, and BEAM is our current standard conditioning
regimen for NHL. A confounding factor affecting TILC is the
clinical status of the patient prior to transplantation. Patients
in CR or PR and better controlled disease could have waited
longer compared with patients with a history of rapid relapses
and higher tumour growth rates that might be moved to have
an ASCT and stem cell collection sooner and inherited had a
worse prognosis. However, both groups were balanced for the
clinical status prior to transplantation and only 5% of patients
were in 1st or 2nd relapse and refractory disease. No
independent correlation was identiﬁed between PA-ALC and
patients’ baseline characteristics and prognostic factors except
for TILC in our cohort of NHL patients. Herein, we present
data supporting the observation that PA-ALC is directly
inﬂuence on the TILC with direct impact on clinical outcomes.
Our study shows a strong correlation between the TILC and
PA-ALC at the time of aphaeresis for ASCT in NHL. Patients
with a TILC ‡55 d achieved a higher PA-ALC compared with
those who did not. The higher PA-ALC translated with a
higher A-ALC collection as a strong correlation between PA-
ALC and A-ALC was again observed in this study. Conse-
quently, the higher A-ALC collected because of the higher PA-
ALC in the TILC ‡55 d translated into a higher ALC-15
recovery and superior OS and PFS in this group compared
with patients with a TILC <55 d. Others (Mackall et al, 1995)
have reported that immunological recovery (including ALC) is
delayed after chemotherapy and that ALC increases over time.
However, no consideration has been given to the impact of
time to immune recovery after chemotherapy and survival, and
speciﬁcally in the ASCT setting.
The discovery that the autograft immune content directly
affects immune recovery and survival post-ASCT is changing
the concept of the autograft from a collection of stem cells
for haematological engraftment post-ASCT to an adoptive
immunotherapeutic strategy to improve immune recovery and
survival post-ASCT, similar to the concept of donor lympho-
cyte infusion (Porrata & Markovic, 2004). However, in this
case, the immunotherapeutic manoeuvre would be an auto-
logous lymphocyte infusion (Porrata et al, 2006). Recently,
Dean et al (2005) reported that higher dendritic cells autograft
content and recovery post-ASCT translated in superior survi-
val in patients with diffuse large cell lymphoma. We have
demonstrated that patients that collected and were infused
with higher A-ALC resulted in better survival compared with
Table III. Univariate analysis for overall and PFS.
Factors
Overall survival PFS
RR 95% CI P-value RR 95% CI P-value
Age ‡60 vs. <60 years 1Æ144 0Æ908-1Æ427 0Æ248 1Æ114 0Æ898–1Æ369 0Æ319
CR vs. other 0Æ957 0Æ687–1Æ274 0Æ776 0Æ941 0Æ693–1Æ230 0Æ679
Extra-nodal sites ‡2 vs. <2 1Æ412 0Æ837–2Æ111 0Æ176 1Æ107 0Æ612–1Æ713 0Æ699
IPI ‡2 vs. <2 1Æ388 1Æ072–1Æ664 <0Æ0103 1Æ307 1Æ064–1Æ600 <0Æ011
LDH >normal 1Æ321 1Æ052–1Æ646 <0Æ017 1Æ291 1Æ043–1Æ586 <0Æ0197
PS ‡2 vs. <2 1Æ615 1Æ004–2Æ353 <0Æ0482 1Æ311 0Æ777–1Æ955 0Æ277
Stage III/IV vs. I/II 1Æ069 0Æ853–1Æ359 0Æ567 1Æ052 0Æ853–1Æ314 0Æ641
TILC (continuous variable) 0Æ989 0Æ980–0Æ997 <0Æ01 0Æ992 0Æ984–0Æ999 <0Æ0492
TILC ‡55 d vs. <55 d 0Æ685 0Æ542–0Æ857 <0Æ0008 0Æ733 0Æ592–0Æ900 <0Æ0028
CR, complete remission; IPI, international prognostic index; LDH, lactate dehydrogenase; PS, performance status; RR, relative risk; TILC, time
interval from last chemotherapy.
Table IV. Multivariate analysis for overall and PFS.
Factors
Overall survival Progression-free survival
RR 95% CI P-value RR 95% CI P-value
IPI ‡2 vs. <2 1Æ192 0Æ917–1Æ539 0Æ187 1Æ279 1Æ041–1Æ567 <0Æ0195
LDH >normal 1Æ162 0Æ887–1Æ509 0Æ273
PS ‡2 vs. <2 1Æ217 0Æ740–1Æ839 0Æ41
TILC ‡55 d vs. <55 d 0Æ703 0Æ555–0Æ880 <0Æ002 0Æ746 0Æ602–0Æ916 <0Æ0195
IPI, international prognostic index; LDH, lactate dehydrogenase; PS, performance status; RR, relative risk; TILC, time interval from last chemotherapy.
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reported that premobilisation T-cell status was associated with
survival after ASCT. All these ﬁndings support the concept that
an immunocompetent host at the time of aphaeresis collection
translates into better survival after ASCT.
However, not many patients have the luxury of waiting for
2 months to allow for their immune system to recover before
proceeding with ASCT. Therefore, autologous immunological
graft engineering is warranted (Porrata et al, 2005). Methods
to engineer an autologous graft-versus-tumor effect in ASCT
include: ex vivo expansion and stimulation of autologous T
cells and natural killer cells (Lapport et al, 2003; Rapaport
et al, 2005); the development of autologous lymphocyte
mobilisation regimens (i.e. cytokines) to augment the number
of immune effector cells into PA-ALC for collection (Sosman
et al, 2001); and autograft lymphocytes harvesting strategies,
such as maximising the capacity of the aphaeresis machine to
collect more immune effector cells (Katipamula et al, 2006).
We hope that these data will support further investigation
aimed at maximising patients’ immunological status at the
time of ASCT.
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